A Company Leading Improvements in the Quality of Healthcare Worldwide
First written in FY2017. 8 of 17 entries say "Advanced", first in FY2019-Q1. Latest entry: FY2024-Q1.
Shimadzu moved to the "Worse" side of this theme in 2023.
0 other companies' latest entry also says "Reframed".
- FY2024-Q1ReframedAnnual report
「As a result, net sales in this business were ¥14,384 million, down 12.5% year on year, while operating income was ¥39 million, down 83.8%, due to lower sales and other factors.」
Although the medical equipment business maintained operating profit, revenue declined 12.5% and operating profit declined 83.8% due to lower domestic revenue, shifting from progress in earnings improvement to a structure involving lower profit. - FY2023-Q3ReframedAnnual report
「As a result, net sales in this business were ¥53,420 million, up 14.0% year on year, while operating income was ¥3,755 million, down 9.0%, due to the impact of soaring parts and material prices and other factors.」
The medical equipment business recorded higher revenue as capital investment recovered, while operating profit declined year on year due to higher prices for parts and materials. - FY2023-Q1ReframedAnnual report
「As a result, net sales in this business were ¥16,434 million, up 13.4% year on year, while operating income was ¥245 million, down 72.3%, due to soaring parts and material prices and other factors.」
The medical equipment business recorded higher revenue, but its earnings mix has shifted toward lower operating income year on year due to surging parts and materials prices. - FY2022AdvancedAnnual report
「Revenue in this business was ¥6,689.4 million, down 0.0% year on year, while operating profit increased 21.8% to ¥608.3 million, due mainly to strong performance in the aftermarket business.」
Although revenue in the medical equipment business was flat, operating profit increased 21.8%, owing in part to strong aftermarket business. - FY2022-Q2RestatedAnnual report
「As a result, revenue from this business was ¥32.058 billion, up 4.7% year on year, and operating profit was ¥2.691 billion, up 92.4%, due to higher revenue and other factors.」
The medical systems business reported higher sales and operating income against a backdrop of recovering demand, mainly in Japan, and has continued to generate operating income. - FY2022-Q1AdvancedAnnual report
「As a result, revenue in this business was ¥14.487 billion, up 10.5% year on year, while operating income was ¥887 million, up 365.8%, due mainly to higher revenue.」
The Medical Systems business recorded higher revenue, while operating profit rose sharply from ¥189 million in the same period of the previous year to ¥887 million, indicating continued progress in improving profitability. - FY2021ReframedAnnual report
「As a result, net sales in this business were ¥66,903 million, down 4.7% year on year, while operating income rose 37.0% to ¥4,370 million, reflecting expense controls and other factors.」
The medical systems business shifted to a structure in which operating profit increased 37.0% year on year, despite lower sales, due to measures including cost controls. - FY2021-Q3ReframedAnnual report
「As a result, revenue in this business was ¥46.357 billion, down 7.9% year on year, while operating profit rose 55.8% to ¥2.014 billion due to expense controls and other factors.」
Although the medical equipment business recorded lower sales, its business mix has shifted toward a 55.8% year-on-year increase in operating profit owing to cost controls and other factors. - FY2021-Q2ReframedAnnual report
「As a result, revenue from this business was ¥30,618 million, down 12.2% year on year, as the substantial decline in Japan could not be offset by higher overseas revenue. Operating profit was ¥1,114 million, down 20.9%, due mainly to the decline in revenue.」
The medical equipment business recorded operating profit, but both revenue and operating profit declined year on year due to a substantial decline in Japan and postponement of capital investment and other factors. - FY2021-Q1AdvancedAnnual report
「As a result, revenue from this business was ¥13.106 billion, down 2.1% year on year, while operating profit was ¥43 million, due to thorough cost controls and other measures (compared with an operating loss of ¥512 million in the same period of the previous year).」
Although the medical equipment business reported lower revenue, it turned from an operating loss to operating profit of ¥43 million, indicating concrete progress in improving profitability. - FY2020AdvancedAnnual report
「As a result, revenue from this business was ¥70,178 million, up 1.6% year on year, and operating profit was ¥3,190 million, up 37.1%.」
The Medical Systems business recorded higher revenue and operating profit for the full year, with operating profit up 37.1% year on year. - FY2020-Q3RestatedAnnual report
「As a result, revenue in this business was ¥50.317 billion, up 2.5% year on year, while operating income was ¥1.292 billion, up 39.1%, due mainly to higher revenue.」
The Medical Systems business recorded higher revenue and profit year on year, and has continued to record operating profit. - FY2020-Q2AdvancedAnnual report
「As a result, revenue from this business was ¥34.876 billion, up 6.8% year on year, while operating profit was ¥1.409 billion, up 105.6%, due mainly to higher revenue.」
The medical equipment business posted a 6.8% year-on-year increase in sales and operating profit of ¥1.409 billion, up 105.6%, indicating concrete progress in improving profitability. - FY2019-Q3AdvancedAnnual report
「As a result, revenue from this business was ¥49.105 billion, up 7.9% year on year, while operating profit was ¥929 million, up 37.4%, owing mainly to higher revenue.」
In the Medical Systems business, operating profit increased from ¥685 million in the previous quarter to ¥929 million for the first 3 quarters of the fiscal year, while revenue also increased 7.9% year on year. Specific progress in improving profitability has continued. - FY2019-Q2AdvancedAnnual report
「As a result, revenue in this business was ¥32.648 billion, up 6.6% year on year, while operating profit increased 3.1% to ¥685 million, mainly due to higher revenue.」
The Medical Systems business progressed from the improvement in its operating loss in the previous quarter, recording operating profit of ¥685 million for the cumulative second quarter. The disclosure specifies that profitability has improved to the point of achieving profitability. - FY2019-Q1AdvancedAnnual report
「As a result, revenue in this business amounted to ¥14.217 billion, up 7.4% year on year, while the operating loss improved due in part to higher overseas sales, amounting to ¥124 million, compared with an operating loss of ¥583 million in the same period of the previous year.」
In the Medical Systems business, the operating loss narrowed from ¥583 million in the previous corresponding period to ¥124 million, mainly due to higher overseas sales and other factors, indicating specific progress in improving profitability. - FY2017First statedAnnual report
「We aim to become “a company leading improvements in the quality of healthcare worldwide,” while making earnings improvement our top priority and developing competitive products and services and expanding our overseas business.」
First presentation of the medical equipment business’s medium- to long-term target position.